Pharmacology and Therapeutics Advisory Committee (PTAC)
PTAC is PHARMAC’s primary clinical advisory committee established under the New Zealand Public Health and Disability Act 2000, section 50 (1)(external link). PTAC's role is to provide objective clinical advice to PHARMAC.
The activities PTAC undertakes for PHARMAC are listed in the Terms of Reference for the Pharmacology and Therapeutics Committee (PTAC) and PTAC subcommittees 2016 [PDF, 834 KB].
Meet our advisers: What is PTAC?
Transcript of Mark Weatherall video
PTAC forms part of the whole PHARMAC process, and the particular role of PTAC is to provide objective clinical advice to assist PHARMAC in making its decisions about how to use its funds wisely.
A central part of what PTAC does is, because patients are at the centre of what PTAC talks about - we're all clinicians dealing with real patients and their families - we can bring that evidence-based perspective but also in relation to its application to real people in New Zealand.
Well, I think there's actually an emotional commitment to doing the best for New Zealanders. In terms of technical skills an ability to think critically, and have an awareness of the application of evidence, its limitations, its strengths, to the decision-making process but also to have patients at the heart of the decision making process in relation to medications.
PTAC is made up of senior health practitioners from a range of specialities, who consider clinical evidence for funding applications, and take into account PHARMAC's Factors for Consideration before making recommendations to PHARMAC.
PHARMAC decides what will be funded, considering all the options for funding, to ensure we are getting the best possible health outcomes for New Zealand.
Following PTAC meetings, PHARMAC considers the funding applications using our Factors for Consideration framework, and compares and ranks them against other funding applications we have received.
Meet our advisers: PTAC members
Transcript of PTAC members video
Prof Mark Weatherall (Chair)
PTAC's role for PHARMAC is very important. It provides objective advice about the use of medicines for New Zealanders.
Dr Jane Thomas, anaesthetist, Auckland
Being able to be part of PTAC discussions and to be an advocate for children within New Zealand where there are great disparities, not just related to age but also socio-economic status, that's a privilege for me to be able to be on PTAC to represent children across New Zealand.
Prof Stephen Munn, transplant surgeon, Auckland
What I'm hopeful is, is that the work itself will contribute to the wellbeing of New Zealanders.
Dr Matthew Strother, medical oncologist, Christchurch
A lot of my interest in participating in this process is driven by that desire to see good access to medicines and having seen what poor access to medicines does to a population.
Prof Tim Stokes, GP, Dunedin
I'm sure that we all feel really strongly that by being on this committee we can make really good recommendations for care that will actually make a real difference in terms of improving the health of New Zealanders.
Dr Melissa Copland, clinical pharmacist, Queenstown
For me what's most rewarding is the way the committee works together. There's a wide range of experience, a wide range of views and often those are expressed very robustly and we have a lot of discussion. But there's a lot of mutual respect and we all are very much working towards a common goal.
Dr Giles Newton-Howes, clinical psychiatrist, Wellington
For me medicine's always been about caring for the person in front of us and caring for all of the people we don't see and I guess part of the reason I ended up doing academia is good quality research helps hopefully lots and lots of patients who you'll never see and actually that's exactly what PHARMAC does.
Dr Sean Hanna, GP, Porirua
There aren't many committees in health where the decisions that are made make a real difference and for me that's why I love being on PTAC.
- Mark Weatherall (Chair) - Internal Medicine - Geriatric
BA, MBChB, MApplStats, FRACP
- Marius Rademaker (Deputy Chair) - Dermatologist
BM (Soton), MRCP (UK), JCHMT Accreditation, DM, FRCP (Edin), FRACP
- Brian Anderson – Anaesthesia & Intensive Care Medicine Specialist
MB ChB, Dip Obst, FANZCA, FCICM, PhD
- Melissa Copland - Pharmacist
PhD, BPharm(Hons), RegPharmNZ, FNZCP
- Alan Fraser - Gastroenterologist
MB, ChB, MD, FRACP
- Sean Hanna - General Practitioner
MB ChB, FRNZCGP, FRACGP, PGDipGP, PGDipClinEd
- Jennifer Martin - Clinical Pharmacologist
MBChB, MA(Oxon.), FRACP, PhD
- Stephen Munn - Transplant Surgeon
MBChB, FRACS, FACS
- Giles Newton-Howes - Psychiatrist
BA, BSc, MBChB, MRCPsych, PostDip BD, FRANZCP
- Tim Stokes - General Practitioner
MA, MBChB, MPH, PhD, FRCP, FRCGP, FRNZCGP
- Matthew Strother - Medical Oncologist
MD (USA), FRACP
- Jane Thomas - Paediatric Anaesthesia and Pain Medicine Specialist
MBChB, FANZCA, FFPMANZCA
- Simon Wynn Thomas - General Practitioner
BMedSci (UK), MRCP (UK), MRCGP (UK), DFFP, FRNZCGP
PTAC members are appointed by the Director-General of Health, in consultation with the PHARMAC Board. This process is guided by an appointment protocol [PDF, 72 KB].
Interested senior health practitioners can apply directly or are nominated by professional medical bodies, such as the Royal New Zealand College of General Practitioners and the Royal Australasian College of Physicians. Vacancies are posted on the PHARMAC careers page(external link).
PHARMAC’s Operating Policies and Procedures set out the procedures for making amendments to the pharmaceutical schedule, including PTAC’s role in the process.
Information on how to apply is on the New funding applications page.
When applying please ensure that the application is complete, providing the following with the initial copy of the funding application:
- A spiral bound copy of the application (including synopsis and all supporting references), and
- an electronic copy of the application (including synopsis and all supporting references). Unlocked PDF copies of all documentation on a USB/memory stick are appreciated.
Please note Named Patient Pharmaceutical Assessment (NPPA) applications are not reviewed by PTAC. If you wish to submit a NPPA application please see the NPPA page.
If PHARMAC chooses to seek PTAC advice on a funding application the application must have been received by the following dates in order to be available for consideration at one of PTAC’s four annual meetings.
|Deadline for an application to be received by PHARMAC, to be considered by PTAC:||PTAC’s meeting date:|
|11 November 2019||20 & 21 February 2020|
|24 February 2020||21 & 22 May 2020|
|25 May 2020||20 & 21 August 2020|
|10 August 2020||19 & 20 November 2020|
Address funding applications to:
40 Mercer Street
PHARMAC will assess the initial funding application and notify the applicant whether:
- it will be considered by PTAC
- it will beconsidered by a PTAC subcommittee, or
- further information is required before an assessment can be made.
We will advise applicants if we require additional material (ie copies and/or a sample of the pharmaceutical) or if the application is not in scope for PHARMAC’s assessment. Below are the dates when additional information is needed if it is required for a PTAC meeting.
The November 2019 PTAC meeting will review the applications below. Note this is draft and subject to change:
- Multiple sclerosis treatment – widening access criteria
- Cladribine - relapsing-remitting multiple sclerosis
- Sirolimus - widening access to include lymphovascular malformations
- mTOR inhibitors for the treatment of renal angiomyolipoma and refractory seizures associated with tuberous sclerosis complex
- TNF Alpha Inhibitors - amendment to juvenile idiopathic arthritis criteria
- Tacrolimus suppository – rectal inflammation
- Adalimumab & infliximab - drug monitoring Inflammatory bowel disease
- Adalimumab - ulcerative colitis
- PTAC Minutes - 2019-05 (published 1 August 2019) [PDF, 787 KB]
- PTAC Minutes - 2019-02 (published 8 May 2019) [PDF, 796 KB]
- PTAC minutes – 2018-11 (updated 7 March 2019) [PDF, 364 KB]
- PTAC minutes – 2018-08 (published 23 October 2018) [PDF, 665 KB]
- PTAC minutes – 2018-05 (published 25 July 2018) [PDF, 267 KB]
- PTAC minutes – 2018-02 (published 6 May 2018) [PDF, 640 KB]
- PTAC minutes – 2017-11 (updated 17 May 2018) [PDF, 764 KB]
- PTAC minutes – 2017-08 (published 13 November 2017) [PDF, 601 KB]
- PTAC minutes – 2017-05 (published 10 August 2017) [PDF, 534 KB]
- PTAC minutes – 2017-02 (published 12 May 2017) [PDF, 879 KB]
Minutes from 2002 to 2016
- PTAC minutes – 2016-11 (published 13 February 2017) [PDF, 295 KB]
- PTAC minutes – 2016-08 (published 4 November 2016) [PDF, 348 KB]
- PTAC minutes – 2016-05 (published 15 July 2016, updated 20 December 2016) [PDF, 1.2 MB]
- PTAC minute – 2016-05 (nivolumab) (published 18 May 2016) [PDF, 87 KB]
- PTAC minutes – 2016-02 (updated 25 November 2016) [PDF, 847 KB]
- PTAC minutes – 2015-11 [PDF, 1.4 MB]
- PTAC minute – 2015-11 (pembrolizumab) [PDF, 65 KB]
- PTAC minutes – 2015-08 [PDF, 378 KB]
- PTAC minutes – 2015-05 [PDF, 909 KB]
- PTAC minutes – 2015-02 [PDF, 498 KB]
- PTAC minutes – 2014-11 [PDF, 653 KB]
- PTAC minutes – 2014-08 [PDF, 240 KB]
- PTAC minutes – 2014-05 [PDF, 286 KB]
- PTAC minutes – 2014-02 [PDF, 349 KB]
- PTAC minutes – 2013-11 [PDF, 206 KB]
- PTAC minutes – 2013-08 [PDF, 174 KB]
- PTAC minutes – 2013-05 [PDF, 224 KB]
- PTAC minutes – 2013-02 [PDF, 191 KB]
- PTAC minutes – 2012-11 [PDF, 192 KB]
- PTAC minutes – 2012-08 [PDF, 192 KB]
- PTAC minutes – 2012-05 [PDF, 181 KB]
- PTAC minutes – 2012-02 [PDF, 169 KB]
- PTAC minutes – 2011-11 [PDF, 304 KB]
- PTAC minutes – 2011-09 [PDF, 18 KB]
- PTAC minutes – 2011-08 [PDF, 217 KB]
- PTAC minutes – 2011-05 [PDF, 190 KB]
- PTAC minutes – 2011-03 [PDF, 26 KB]
- PTAC minutes – 2011-02 [PDF, 196 KB]
- PTAC minutes – 2010-11 [PDF, 287 KB]
- PTAC minutes – 2010-08 [PDF, 212 KB]
- PTAC minutes – 2010-05 [PDF, 205 KB]
- PTAC minutes – 2010-02 [PDF, 243 KB]
- PTAC minutes – 2009-11 [PDF, 147 KB]
- PTAC minutes – 2009-08 [PDF, 149 KB]
- PTAC minutes – 2009-05 [PDF, 129 KB]
- PTAC minutes – 2009-02 [PDF, 201 KB]
- PTAC minutes – 2008-11 [PDF, 184 KB]
- PTAC minutes – 2008-07 [PDF, 231 KB]
- PTAC minutes – 2008-07 (teleconference - trastuzumab) [PDF, 55 KB]
- PTAC minutes – 2008-05 [PDF, 205 KB]
- PTAC minutes – 2008-02 [PDF, 208 KB]
- PTAC minutes – 2007-11 [PDF, 181 KB]
- PTAC minutes – 2007-08 [PDF, 168 KB]
- PTAC minutes – 2007-05 [PDF, 103 KB]
- PTAC minutes – 2007-02 [PDF, 187 KB]
- PTAC minute – 2007-02 (Item 9: Trastuzumab/Herceptin) [PDF, 36 KB]
- PTAC minutes – 2006-11 [PDF, 151 KB]
- PTAC minute – 2006-11 (Item 25.4 Trastuzumab/Herceptin) [PDF, 444 KB]
- PTAC minutes – 2006-08 [PDF, 198 KB]
- PTAC minute – 2006-08 (Item 20: Trastuzumab/Herceptin new data) [PDF, 31 KB]
- PTAC minutes – 2006-05 [PDF, 165 KB]
- PTAC minute – 2006-05 (trastuzumab) [PDF, 26 KB]
- PTAC minutes – 2006-02 [PDF, 41 KB]
- PTAC minute – 2006-02 (trastuzumab) [PDF, 30 KB]
- PTAC minutes – 2005-11 [PDF, 150 KB]
- PTAC minutes – 2005-08 [PDF, 111 KB]
- PTAC minutes – 2005-05 [PDF, 99 KB]
- PTAC minutes – 2005-02 [PDF, 113 KB]
- PTAC minutes – 2004-11 [PDF, 97 KB]
- PTAC minutes – 2004-08 [PDF, 34 KB]
- PTAC minutes – 2004-05 [PDF, 18 KB]
- PTAC minutes – 2004-02 [PDF, 81 KB]
- PTAC minutes – 2003-11 [PDF, 135 KB]
- PTAC minutes – 2003-08 [PDF, 61 KB]
- PTAC minutes – 2003-05 [PDF, 21 KB]
- PTAC minute – 2003-05 (Alzheimer's treatments) [PDF, 11 KB]
- PTAC minutes – 2003-02 [PDF, 43 KB]
- PTAC minutes – 2002-11 (metronidazole gel) [PDF, 8.4 KB]
If you have any questions regarding PTAC, please contact the PTAC Secretary at email@example.com or +64 (0)4 916 7512.
Last updated: 17 October 2019